Stanford Starts Endo Pharmacuticals (ENDP) at Buy
More News related to ENDP
- Endo Announces Resignation of Board Member
- Endo Pharmaceuticals (ENDP) Accepts UBS's Settlement Offer Related to Auction Rate Securities
- Endo Pharmaceuticals Announces Acceptance of UBS AG Settlement Offer Relating to Auction Rate Securities
- Caris Upgrades Endo Pharmaceuticals (ENDP) to Buy
- Endo Pharmaceuticals (ENDP) Reports Q3 EPS of $0.64, Beats by 12c
More News related to New Coverage
- After-Hours Movers 12/05: Actuate (ACTU) Up On Higher Tender Offer, RF Micro (RFMD) Lower on Guidance
- Trading Radar for 12/05: Big Lots (BIG), Flow Int'l (FLOW), Blyth (BTH) Report; Nonfarm Payrolls, Unemployment Rate, Consumer Credit Due
- Unusual 11 Mid-Day Movers 12/04: DXCM, TLB, PRKR, PSS Higher; CRUS, DMND, ITWO, DDMX Lower
- Notable Analyst Rating Changes 12/04: AMZN, YRCW, GPN, TRI Upgraded; DMND, DOX, FMCN, ISIL Downgraded
- Morning Movers 12/04: Merck (MRK) Lower On Guidance, Amazon.com (AMZN) Higher On Upgrade
Stanford Group initiates coverage on Endo Pharmacuticals (Nasdaq: ENDP) with a Buy rating.
Endo Pharmaceuticals Holdings, Inc. engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain.
Related Categories
New CoverageStocks Mentioned
-0.50Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
